Three very different people gathered recently at University of Colorado Hospital. They were linked by...
COXEN Model Picks the Best Drug for Ovarian Cancer
February 18, 2014 · No comments
University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.
Study: Beauty Not Disease Motivates Teens to Wear Sunscreen
February 13, 2014 · No comments
"You can tell that when we talk [to teens] about the skin cancer risk, it doesn’t faze them. But when you talk about premature wrinkling and aging, they listen a little more closely," says April W. Armstrong, MD MPH, investigator at the CU Cancer Center.
"It may be that childhood obesity changes the way the whole metabolism is working – and changes it during a critical developmental time frame," says Kristen Nadeau, MD.
A study recently published in the journal Biology of Blood and Marrow Transplantation shows that in the case of a child's stem cell transplant, parents feel increased distress at the time of the procedure, but eventually recover to normal levels of adjustment.
3D Mapping Biopsy Finds 3x Prostate Cancer of Ultrasound-Guided Biopsy
February 4, 2014 · Comments Off
CU Cancer Center study shows common locations of prostate cancers missed by ultrasound-guided biopsy.
Lung and bladder cancers have common cell-cycle biomarkers
January 29, 2014 · Comments Off
CU Cancer Center study: bladder and lung cancers are marked by shared differences in the genetics that control the cell cycle.
“Weeding the garden” with radiation allows ALK+ lung cancer patients to continue crizotinib, increasing survival
January 28, 2014 · Comments Off
CU Cancer Center study shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease. Eliminating these pockets of resistant disease allows patients to continue treating the overall condition with crizotinib, leading to improved 2-year survival rate compared with patients forced to discontinue the drug sooner.
NTRK1: a new oncogene and target in lung cancer
January 28, 2014
ALK alk drug lung cancer ALL amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno biomarkers bladder cancer breast cancer cancer grants cancer research colorado Cancer Survivorship cell signaling clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma metastasis Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge screening skin cancer tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
I posted 45 photos on Facebook in the album "Dress In Blue 2014" http://t.co/p7qOfCsqKJ
Thank you to everyone who attended last week's Dress in Blue Eve event at Breckenridge Brewery and for all those... http://t.co/tcoNIu75up
Today is the day! Enjoy some blueberry pancakes and dress in all blue for Dress in Blue day to increase... http://t.co/LnYh9iT1lW
One last reminder. Wear blue tomorrow for Dress in Blue Day! http://t.co/dNKEDueKNv
In Health Care, Choice Is Overrated. We're glad our patient got the second opinion needed. Hope others can too. http://t.co/3T9CrAj8E2